|
|
 |
|
Viewing report
|
|
|
|
China Pharmaceutical Market Overview
Datamonitor, Nov 2010, Pages: 244
The Chinese hospital prescription pharma market generated sales of $22.9 billion in 2009, with an annual growth rate of 26.5% between 2008 and 2009. Key growth drivers include China’s support of foreign direct investment, low operating costs, growing economic wealth and a government stimulus of $125 billion to be spent on healthcare reforms during 2009–2011.
Scope
- Overview of socioeconomic and demographic trends, healthcare system, regulation, pricing and reimbursement and intellectual property position in China
- Assesses the size of the Chinese pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies
- Examines the Chinese generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion
- Quantifies the R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis
Report Highlights:
The combination of China’s rising population to 2030, plus the expansion of the elderly population, as a proportion of the total population, will create additional pressure on the government in terms of healthcare provision especially for the elderly.
According to the Ministry of Health, by the end of October 2010, the three public health insurance schemes covered 1,233 million Chinese citizens, accounting for more than 90% of the total population.
Domestic manufacturers dominate the Chinese generics market, accounting for nearly 99% of generics sales of both branded and unbranded generics. The domestic industry has expanded rapidly as companies have improved their manufacturing capacities.
Reasons to Purchase:
- Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access in China
- Quantify the size and growth of the prescription pharmaceutical market in China, analyzing key therapy areas, brands and companies
- Assess drivers and resistors of generic and biosimilars uptake in China
|
|
|
|
